Over the years, we know you've come to expect the best American Society of Clinical Oncology (ASCO) coverage from Biomedtracker. In anticipation of this year's conference, held June 2-6, 2017 in Chicago, we wanted to provide you a summary of the various ways we keep you up-to-date on the biggest oncology event of the year.

May 17 - Pre-ASCO Abstract Release Night Report and Planner
Our coverage kicks off this Wednesday, May 17th, with our annual Abstract Release Night primer. You can expect our coverage of the major, potentially market-moving abstracts released at 5pm EST to be in your inbox when you wake up Thursday morning. In addition to analyses on the important data released, you'll find our useful ASCO planner and a 'Companies to Watch' list. For last year's coverage, see here.

Tentatively May 24 - Pre-Meeting Podcast
As an accompaniment to the Pre-ASCO report, join a panel of Informa Pharma Intelligence analysts as they hold a roundtable discussion of the abstracts to help you navigate the flood of data in the abstract release.

June 5 - ASCO Weekend Update
Along with many events added to the Biomedtracker database over the weekend, our analysts will be attending the ASCO conference and providing their boots-on-the-ground commentary both in our Biomedtracker events, and in a 'Weekend Update', published before you start your day Monday morning. For an example of past Weekend Reports, see here.

Tentatively June 8 - Post-Meeting Podcast
A panel of Informa analysts will discuss the major developments of the conference and key take-aways via a podcast recorded directly after the meeting concludes. Join Biomedtracker's Robert Jeng, Citeline's Maria Berezina, and Datamonitor Healthcare's Dominique Fontanilla as they debrief following the conclusion of the conference with their rapid takeaways and key highlights.

Late June/Early July - Post-ASCO Report
Once our analysts return from the conference and all of the Informa Pharma coverage is completed, the team will publish a comprehensive wrap-up of the conference and provide insights on material updates in various oncology indications. For an example of last year's post-report, see here.